Scientists have long been working on the development of an effective and broad HIV vaccine. A new nanoparticle HIV vaccine candidate seems to be overcoming challenges that previous developments couldn’t address. The candidate helps for the development of antibodies that can neutralise about 90 per cent of HIV strains.

While modern antiretroviral therapies can suppress the human immunodeficiency virus to nearly undetectable levels, there is still no cure for the infection. Cornell researchers have currently received a grant that will allow examination of important cellular mechanisms standing in the way of eliminating the infection. This new research increases the hope of finding a cure.

It’s a well-known fact that HIV affects men disproportionately. The latest annual statistics from the US suggest that high risk groups like men who have sex with men are benefiting from reliable protection in the form of HIV PrEP. PrEP has contributed to a significant slowdown in the number of new infections and the trend has been ongoing ever since 2017.

Research from the US suggests that a new “super” strain of gonorrhoea has already started infecting individual. This strain is resistant to nearly every class of antibiotic used for the treatment of the STD. the situation is considered a public health crisis that necessitates the development of a brand new therapeutic approach.

The scientific community still hasn’t discovered a 100 per cent effective cure for HIV and researchers may know the reason why. A new Johns Hopkins University study suggests that the virus uses complex cellular processes to maintain a solid DNA reservoir. This is even true among individuals receiving antiretroviral therapy.

An STD should be the last thing on your mind when in a relationship but it’s possible to get an infection from your partner (even when you’re in a committed monogamous relationship). Getting the news about a sexually transmitted disease is never easy but you should get yourself together and complete a couple of important steps.

The human immunodeficiency virus employs numerous mechanisms to spread within the human body and remain concealed. A thorough clinical trial suggests how it does so during the early stages of an infection. The findings of the clinical trial also make it clear why antiretroviral therapy could be ineffective in the beginning of an active infection.